百诚医药(301096.SZ)：BIOS2242口服溶液获得临床试验批准

Core Viewpoint - Baicheng Pharmaceutical's subsidiary, Zhejiang Saimer Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug BIOS2242 oral solution, aimed at treating mild to moderate acute ischemic stroke [1] Company Summary - Baicheng Pharmaceutical's subsidiary, Zhejiang Saimer Pharmaceutical, has successfully obtained a clinical trial approval notice for BIOS2242 oral solution from NMPA [1] - The clinical trial application for BIOS2242 was accepted on August 27, 2025, and meets the requirements for drug registration [1] - The approved clinical trial is specifically for the indication of treating mild to moderate acute ischemic stroke [1]